Management of dyslipidemia in adult solid organ transplant recipients

Bruce A. Warden, Paul Duell

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Solid organ transplantation (SOT) has revolutionized treatment of end-stage disease. Improvements in the SOT continuum of care have unmasked a significant burden of cardiovascular disease, manifesting as a leading cause of morbidity and mortality. Although several risk factors for development of post-transplant cardiovascular disease exist, dyslipidemia remains one of the most frequent and modifiable risks. An important contributor to dyslipidemia in SOT recipients is the off-target metabolic effects of immunosuppressive medications, which may alter lipoproteins and their metabolism. Dyslipidemia management is paramount as lipid-lowering therapy with statins has demonstrated reductions in graft vasculopathy, decreased rejection rates, and improved survival. Several nonstatin medication options are available, but data supporting their benefit in the SOT population are minimal, typically extrapolated from studies in the general population. Further compounding dyslipidemia management is the complex interplay of drug interactions between lipid-lowering and immunosuppressant medications, which can result in serious toxicity and/or therapeutic failure.

Original languageEnglish (US)
JournalJournal of clinical lipidology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Organ Transplantation
Dyslipidemias
Transplants
Immunosuppressive Agents
Cardiovascular Diseases
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Continuity of Patient Care
Drug Interactions
Population
Lipoproteins
Therapeutics
Survival Rate
Morbidity
Mortality
Transplant Recipients

Keywords

  • Drug-drug interactions
  • Dyslipidemia
  • Immunosuppression
  • Lipid-lowering therapy
  • Solid organ transplantation

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

Management of dyslipidemia in adult solid organ transplant recipients. / Warden, Bruce A.; Duell, Paul.

In: Journal of clinical lipidology, 01.01.2019.

Research output: Contribution to journalReview article

@article{ebace77c124d4de98dd3d6e1fbe3991a,
title = "Management of dyslipidemia in adult solid organ transplant recipients",
abstract = "Solid organ transplantation (SOT) has revolutionized treatment of end-stage disease. Improvements in the SOT continuum of care have unmasked a significant burden of cardiovascular disease, manifesting as a leading cause of morbidity and mortality. Although several risk factors for development of post-transplant cardiovascular disease exist, dyslipidemia remains one of the most frequent and modifiable risks. An important contributor to dyslipidemia in SOT recipients is the off-target metabolic effects of immunosuppressive medications, which may alter lipoproteins and their metabolism. Dyslipidemia management is paramount as lipid-lowering therapy with statins has demonstrated reductions in graft vasculopathy, decreased rejection rates, and improved survival. Several nonstatin medication options are available, but data supporting their benefit in the SOT population are minimal, typically extrapolated from studies in the general population. Further compounding dyslipidemia management is the complex interplay of drug interactions between lipid-lowering and immunosuppressant medications, which can result in serious toxicity and/or therapeutic failure.",
keywords = "Drug-drug interactions, Dyslipidemia, Immunosuppression, Lipid-lowering therapy, Solid organ transplantation",
author = "Warden, {Bruce A.} and Paul Duell",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jacl.2019.01.011",
language = "English (US)",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Management of dyslipidemia in adult solid organ transplant recipients

AU - Warden, Bruce A.

AU - Duell, Paul

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Solid organ transplantation (SOT) has revolutionized treatment of end-stage disease. Improvements in the SOT continuum of care have unmasked a significant burden of cardiovascular disease, manifesting as a leading cause of morbidity and mortality. Although several risk factors for development of post-transplant cardiovascular disease exist, dyslipidemia remains one of the most frequent and modifiable risks. An important contributor to dyslipidemia in SOT recipients is the off-target metabolic effects of immunosuppressive medications, which may alter lipoproteins and their metabolism. Dyslipidemia management is paramount as lipid-lowering therapy with statins has demonstrated reductions in graft vasculopathy, decreased rejection rates, and improved survival. Several nonstatin medication options are available, but data supporting their benefit in the SOT population are minimal, typically extrapolated from studies in the general population. Further compounding dyslipidemia management is the complex interplay of drug interactions between lipid-lowering and immunosuppressant medications, which can result in serious toxicity and/or therapeutic failure.

AB - Solid organ transplantation (SOT) has revolutionized treatment of end-stage disease. Improvements in the SOT continuum of care have unmasked a significant burden of cardiovascular disease, manifesting as a leading cause of morbidity and mortality. Although several risk factors for development of post-transplant cardiovascular disease exist, dyslipidemia remains one of the most frequent and modifiable risks. An important contributor to dyslipidemia in SOT recipients is the off-target metabolic effects of immunosuppressive medications, which may alter lipoproteins and their metabolism. Dyslipidemia management is paramount as lipid-lowering therapy with statins has demonstrated reductions in graft vasculopathy, decreased rejection rates, and improved survival. Several nonstatin medication options are available, but data supporting their benefit in the SOT population are minimal, typically extrapolated from studies in the general population. Further compounding dyslipidemia management is the complex interplay of drug interactions between lipid-lowering and immunosuppressant medications, which can result in serious toxicity and/or therapeutic failure.

KW - Drug-drug interactions

KW - Dyslipidemia

KW - Immunosuppression

KW - Lipid-lowering therapy

KW - Solid organ transplantation

UR - http://www.scopus.com/inward/record.url?scp=85063381560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063381560&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2019.01.011

DO - 10.1016/j.jacl.2019.01.011

M3 - Review article

C2 - 30928441

AN - SCOPUS:85063381560

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

ER -